ZYDUSCADILA is a Leading INDIAN Multinational Drugs Manufacturing Company, Located at Ahmedabad, Gujrat, India. Fully integrated Globally Health Care Products Provider and Generic Drugs. Company was Established in 1952 by RAMANBHAI PATEL with his Business Partner INDRAVADAN MODI . It ranked 100th in the Fortune INDIA 500 list in 2020.
In 1995 the PATEL and MODI families Split and The Modi family's was moved in to a new Company called CADILA PHARMACEUTICALS LTD and Company became the Patel families holding Company.
In 2015 the Company acquired another Indian Pharmaceutical Company GERMAN REMEDIES. On june 25th 2007,the Company acquired QUIMICA e FARMACEUTICA NIKKHO DO BRASIL LTD.
In 2010, CADILA HEALTHCARE Received a WELLCOME TRUST Award under the R&D for Affordable Healthcare in INDIA initiate The world's first ADALIMUMAB BIOSIMILAR under the brand name EXEMPTA at 1/5 the Originator's Price. Company has also Launched its first research based drug molecule Sarogliter in treatment of DIABETIC DYSLIPIDEMUA" under brand name LIPAGLYN. SOVIHEP is the first SOFOSBUVIR brand launched in INDIA in the Year 2015.
ZYDUS CADILA is one of the Oldest Indian Formulations player of the market and Prominent Pharmaceutical Manufacture Company in INDIA. ZYDUS CADILA is improving its presence in the Market Share Continuously and Company Manufacturing Both pharmaceutical Products for HUMAN'S& ANIMAL'S.
ZYDUS CADILA was Manufactured , In the year 2019, INJECTABLE KETOROLAC Tromethamine due to his 'MICROBIAL' Growth and Permitted by USFDA to initiate Clinical Trials for CANCER Patients. Company develops and manufactures a Large Range of Pharmaceuticals, Herbals, Skincare and other Products. Company Start from 2015, Having Concluded a Voluntarily License Agreement with GILEAD and also Products the GENERICS for HEPATITIS C Treatments. The Company has three places in INDIA, For Manufacturing of ACTIVE PHARMACEUTICAL INGREDIENTS
1. VARODARA
2. ANKLESHWAR
3. PATALGANGA
The Company decided to develop a DNA PLASMID Based COVID -19 VACCINE at their Vaccine Technology Centre VTC in Ahmedabad and able to Pass the Pre- Clinical trials on Animals Model Successfully and Phase -I trials of the Vaccine Started From In JULY - 2020 and Continued to until OCTOBER -2020. The Vaccine was Tested on 48 healthy Peoples in the 18-55 Years of age range and after 28 days between each of the 3rd 'DOSES' and VTC was found the Vaccine to be SAFE & WELL TOLERATED and IMMUNOGENIC . 2ND Phase trials of the Vaccine from 6th AUGUST - 2021 With THOUSANDS of individuals as part of the Adaptive PHASE - I & II for MULTI-CENTRIC, DOSE- ESCALATION, RANDOMISED, DOBLE-BLIND . Placebo Controlled Method and Company was reported PH-II trials were Completed by NOVEMBER - 2020.
The Company Announced the Test of Vaccines with 30thousands Patients PHASE -III trial in November 2020 and reported in JAN-2021.The Drugs Controller General of INDIA, granted Permission to Conduct the trials for 28,216 Indian in the age of 12-99 group and One thousands Individuals were in the 12-18 age group. The Company applied to DGCI for Seeking Approval of RESTRICTED USE IN EMERGENCY SITUATION on AUGUST-2021.The Export Committee of the CENTRAL DRUGS STANDARD CONTROL ORGANISATION recommended that the 'DGCI' grant the Approval on the same day
The Company got Permission to Conduct HUMAN TRIALS of the Developmental for COVID-19 VACCINE in 'JULY-2020', the named as ZYCOV-D from the DGCI , Drugs Controller General of India.
The COVID-19 VACCINE ZYCOV-D, Contains a DNA PLASMID VECTOR ,That Carries the gene Encoding the SPIKE PROTEIN of SARS-COV-2 , As with other DNA VACCINES the Recipients Cells then Produce the SPIKE PROTEIN, ELICITING To Protective IMMUNE response.
The enterprise at ultimate DISCOVERD the WORLD'S & INDIA'S FIRST Needle unfastened PLASMID DNA COVID-19, Vaccine for Adolescents withinside the age organization of 12-18 and Plans directly to Seek APPROVED for TWO DOSE regimen.
1. Target : SARS-Cov-2
2. Vaccine Type : DNA
CLINICAL DATA :
1. Routes of Administration
2. ATC Code : None
LEGAL STATUS : List of ZYCOV-D COVID-19- VACCINE Authorizations.
IDENTIFIERS : Drug Bank Accession Number- DB15892
Posts
